Acceptability of a Tenofovir Disoproxil Fumarate Vaginal Ring for HIV Prevention Among Women in New York City

被引:11
|
作者
Watnick, Dana [1 ,3 ]
Keller, Marla J. [2 ,3 ]
Stein, Kimberly [4 ]
Bauman, Laurie J. [1 ,3 ]
机构
[1] Albert Einstein Coll Med, Dept Pediat, Bronx, NY 10461 USA
[2] Albert Einstein Coll Med, Dept Med, Bronx, NY 10467 USA
[3] Montefiore Med Ctr, 111 E 210th St, Bronx, NY 10467 USA
[4] Tufts Univ, Cummings Sch Vet Med, Medford, MA 02155 USA
基金
美国国家卫生研究院;
关键词
Vaginal ring; Acceptability; Pre-exposure prophylaxis; Women; HIV prevention; MICROBICIDE ACCEPTABILITY; MULTIPURPOSE PREVENTION; ANTIRETROVIRAL PROPHYLAXIS; PREEXPOSURE PROPHYLAXIS; EUROPEAN-AMERICAN; AFRICAN-AMERICAN; SEXUAL PLEASURE; PHASE-I; RISK; INFECTION;
D O I
10.1007/s10461-017-1962-8
中图分类号
R1 [预防医学、卫生学];
学科分类号
1004 ; 120402 ;
摘要
Vaginal rings for pre-exposure prophylaxis are a female-initiated HIV prevention method that does not require daily or coitally-dependent dosing. As part of a randomized placebo-controlled trial of a tenofovir disoproxil fumarate intravaginal ring, we assessed product acceptability through in-depth interviews with 18 women during and after 14 days of continuous use. Women reported that the ring was comfortable with few side effects, regardless of experimental arm. However, interest in future use by this cohort was modest for several reasons including: low self-perceived HIV risk; concern that use implied promiscuity; potential for interference with relationship formation and trust; concern for interference with menstruation and cleanliness; and worries about partners' acceptability and sexual pleasure. Potential issues were raised with duration of use prior to ring exchange. Future studies should continue to identify and address individual and relationship factors that influence acceptability, early in the product development process.
引用
收藏
页码:421 / 436
页数:16
相关论文
共 50 条
  • [1] Acceptability of a Tenofovir Disoproxil Fumarate Vaginal Ring for HIV Prevention Among Women in New York City
    Dana Watnick
    Marla J. Keller
    Kimberly Stein
    Laurie J. Bauman
    [J]. AIDS and Behavior, 2018, 22 : 421 - 436
  • [2] Acceptability of a Polyurethane Tenofovir Disoproxil Fumarate (TDF) Intravaginal Ring for HIV Prevention
    Watnick, Dana L.
    Keller, Marla J.
    Espinoza, Lilia
    Herold, Betsy C.
    Bauman, Laurie J.
    [J]. AIDS RESEARCH AND HUMAN RETROVIRUSES, 2014, 30 : A141 - A142
  • [3] Acceptability of a Tenofovir Disoproxil Fumarate Intravaginal Ring for HIV Pre-Exposure Prophylaxis Among Sexually Active Women
    Dobkin, April
    McWalters, Jessica
    Barnett, Rebecca
    Ray, Laurie L.
    Espinoza, Lilia
    McGinn, Aileen P.
    Atrio, Jessica M.
    Keller, Marla J.
    [J]. SEXUALLY TRANSMITTED DISEASES, 2020, 47 (12) : 819 - 824
  • [4] HIV Preexposure Prophylaxis With Emtricitabine and Tenofovir Disoproxil Fumarate Among Cisgender Women
    Marrazzo, Jeanne
    Tao, Li
    Becker, Marissa
    Leech, Ashley A.
    Taylor, Allan W.
    Ussery, Faith
    Kiragu, Michael
    Reza-Paul, Sushena
    Myers, Janet
    Bekker, Linda-Gail
    Yang, Juan
    Carter, Christoph
    de Boer, Melanie
    Das, Moupali
    Baeten, Jared M.
    Celum, Connie
    [J]. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2024, 331 (11): : 930 - 937
  • [5] Intravaginal ring delivery of tenofovir disoproxil fumarate for prevention of HIV and herpes simplex virus infection
    Mesquita, Pedro M. M.
    Rastogi, Rachna
    Segarra, Theodore J.
    Teller, Ryan S.
    Torres, N. Merna
    Huber, Ashley M.
    Kiser, Patrick F.
    Herold, Betsy C.
    [J]. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 2012, 67 (07) : 1730 - 1738
  • [6] A drug evaluation of 1% tenofovir gel and tenofovir disoproxil fumarate tablets for the prevention of HIV infection
    Gengiah, Tanuja N.
    Baxter, Cheryl
    Mansoor, Leila E.
    Kharsany, Ayesha B. M.
    Karim, Salim S. Abdool
    [J]. EXPERT OPINION ON INVESTIGATIONAL DRUGS, 2012, 21 (05) : 695 - 715
  • [7] Effect of Pregnancy and Concomitant Antiretrovirals on the Pharmacokinetics of Tenofovir in Women With HIV Receiving Tenofovir Disoproxil Fumarate-Based Antiretroviral Therapy Versus Women With HBV Receiving Tenofovir Disoproxil Fumarate Monotherapy
    Bukkems, Vera E.
    Smolders, Elise J.
    Jourdain, Gonzague
    Burger, David M.
    Colbers, Angela P.
    Cressey, Tim R.
    [J]. JOURNAL OF CLINICAL PHARMACOLOGY, 2021, 61 (03): : 388 - 393
  • [8] Intravaginal ring eluting tenofovir disoproxil fumarate completely protects macaques from multiple vaginal simian-HIV challenges
    Smith, James M.
    Rastogi, Rachna
    Teller, Ryan S.
    Srinivasan, Priya
    Mesquita, Pedro M. M.
    Nagaraja, Umadevi
    McNicholl, Janet M.
    Hendry, R. Michael
    Dinh, Chuong T.
    Martin, Amy
    Herold, Betsy C.
    Kiser, Patrick F.
    [J]. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2013, 110 (40) : 16145 - 16150
  • [9] Dose response to tenofovir disoproxil fumarate and tenofovir released via intravaginal ring in the sheep vaginal safety and pharmacokinetics model
    Vargas, G.
    Moss, J. A.
    Pyles, R. B.
    Herold, B.
    Keller, M.
    Baum, M. M.
    Motamedi, M.
    Vincent, K. L.
    [J]. JOURNAL OF THE INTERNATIONAL AIDS SOCIETY, 2021, 24
  • [10] Intracellular Tenofovir and Emtricitabine Concentrations in Younger and Older Women with HIV Receiving Tenofovir Disoproxil Fumarate/Emtricitabine
    Dumond, Julie B.
    Bay, Camden P.
    Nelson, Julie A. E.
    Davalos, Angel
    Edmonds, Andrew
    De Paris, Kristina
    Sykes, Craig
    Anastos, Kathryn
    Sharma, Roopali
    Kassaye, Seble
    Tamraz, Bani
    French, Audrey L.
    Gange, Stephen
    Ofotokun, Ighovwerha
    Fischl, Margaret A.
    Vance, David E.
    Adimora, Adaora A.
    [J]. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2020, 64 (09)